2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148573
    sEH inhibitor-14 2890221-26-6 98%
    sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC50=0.39 nM).
    sEH inhibitor-14
  • HY-148625
    PDE9-IN-2 917089-10-2 98%
    PDE9-IN-2 (compound 6) is a PDE9 inhibitor that improves heart failure.
    PDE9-IN-2
  • HY-148651
    CDK2-IN-15 1219915-83-9 98%
    CDK2-IN-15 (Compound 19) is an inhibitor of CDK2 with an IC50 of 2.9 μM. CDK2-IN-15 can be used for cancer research.
    CDK2-IN-15
  • HY-148670
    Pulmonary arterial hypertension agent-1 1201082-00-9 98%
    Pulmonary arterial hypertension agent-1 (example 15) is a pulmonary arterial hypertension agent. Pulmonary arterial hypertension agent-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Pulmonary arterial hypertension agent-1
  • HY-149094
    Neuroprotective agent 1 2344786-13-4 98%
    Neuroprotective agent 1 (2), a promising neuroprotective agent for the study of ischemic stroke, shows promising neuroprotective activity with the EC50 value of 16.07 μM in the model of glutamate-induced excitotoxicity and 19.30 μM in the model of H2O2-induced oxidative damage.
    Neuroprotective agent 1
  • HY-149101
    Riboxin 86-04-4 98%
    Riboxin (IDP), an orally active purine derivative-hypoxanthine rlboside, has antihypoxic and antihyperthermic activity. Riboxin also has an antiarrhythmic action in cats, rabbits, and mice with cardiac rhythm disorders induced by Ouabain. Riboxin protects animals against the noxious effects of γ-irradiation.
    Riboxin
  • HY-149173
    CDK-IN-11 2376876-87-6 98%
    CDK-IN-11 is a heterocyclic compound that has an action of promoting cardiomyocyte maturation.
    CDK-IN-11
  • HY-149260
    HIF-1 inhibitor-5 98%
    HIF-1 inhibitor-5 (Compound 16e) is a potent HIF-1 inhibitor with an IC50 of 2.38 μM. HIF-1 inhibitor-5 possesses anti-angiogenic potential.
    HIF-1 inhibitor-5
  • HY-149288
    hAChE/hBACE-1-IN-2 98%
    hAChE/hBACE-1-IN-2 is a potent, orally active, blood-brain barrier transboundary triple inhibitor of hAChE, hBChE, and HACE-1 with IC50s of 0.113 μM, 1.48 μM and 0.38 μM, respectively. hAChE/hBACE-1-IN-2 has antioxidant activity. hAChE/hBACE-1-IN-2 also inhibits Aβ11-42 aggregation. hAChE/hBACE-1-IN-2 can be used to study Alzheimer's disease.
    hAChE/hBACE-1-IN-2
  • HY-149351
    NF-κB-IN-10 3052257-09-4 98%
    NF-κB-IN-10 (compound E1) is an NF-κB inhibitor that can improve heart failure by reducing oxidative stress and inflammation by regulating Nrf2/NF-κB signaling pathway. NF-κB-IN-10 inhibits LPS-induced NO production and expression of iNOS and COX-2 in RAW264.7 cells. NF-κB-IN-10 can be used in the research of cardiovascular diseases.
    NF-κB-IN-10
  • HY-149396
    FXIIa-IN-1 3052551-19-3 98%
    XIIa-IN-1-IN-3 (Compound 22) is a Factor XIIa inhibitor (Kiapp: 97.8 nM). XIIa-IN-1-IN-3 can be used for research of thrombosis.
    FXIIa-IN-1
  • HY-149462
    KN1022 205255-11-4 98%
    KN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC50 of 0.24 μM.
    KN1022
  • HY-149661
    PDE5-IN-11 98%
    PDE5-IN-11 is a potent inhibitor of PDE5 with an IC50 of 40 nM. PDE5-IN-11 also inhibits PDE4 and PDE6 with IC50s of 1.78 and 0.09 μM, respectively.
    PDE5-IN-11
  • HY-149736
    ATP Synthesis-IN-3 3032416-36-4 98%
    ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis.
    ATP Synthesis-IN-3
  • HY-150022
    GRK5-IN-4 2410794-89-5 98%
    GRK5-IN-4 (Compound 16d, CCG-265328) is a potent and and selective covalent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 1.1 μM. GRK5-IN-4 shows 90-fold selectivity over GRK2. GRK5-IN-4 can be used for heart failure research. GRK5-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    GRK5-IN-4
  • HY-150039
    CCG-271423 2750413-88-6 98%
    CCG-271423 is a potent and selective GRK5 inhibitor with IC50 values of 0.0021 μM and 44 μM for GRK5 and GRK2, respectively. CCG-271423 inhibits cardiomyocyte contractility and decreases in Ca2+ transience. CCG-271423 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CCG-271423
  • HY-150040
    CCG-273463 2750413-99-9 98%
    CCG-273463 is a potent, selective and covalent GRK5 inhibitor with an IC50 value of 8.6 nM. CCG-273463 can be used in the research of heart failure, hypertrophic cardiomyopathy, and cancer.
    CCG-273463
  • HY-150052
    Plasma kallikrein-IN-3 1357950-47-0 98%
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
    Plasma kallikrein-IN-3
  • HY-150092
    8(S),9(R)-EET 123931-39-5 98%
    8(S),9(R)-EET is an eicosanoid product of Arachidonic acid (AA; HY-109590) by cytochromes P450. 8(S),9(R)-EET dilates canine epicardial arterioles in a concentration-dependent manner with an EC50 value of 121 nM.
    8(S),9(R)-EET
  • HY-150682
    FXIa-IN-9 2816108-87-7 98%
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism.
    FXIa-IN-9
Cat. No. Product Name / Synonyms Application Reactivity